nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C9—Capecitabine—colon cancer	0.124	0.441	CbGbCtD
Tolterodine—CHRM3—ureter—colon cancer	0.107	0.362	CbGeAlD
Tolterodine—CHRM3—muscle of abdomen—colon cancer	0.0773	0.261	CbGeAlD
Tolterodine—CYP2C9—Fluorouracil—colon cancer	0.0738	0.262	CbGbCtD
Tolterodine—CYP3A4—Irinotecan—colon cancer	0.0447	0.158	CbGbCtD
Tolterodine—CYP3A4—Vincristine—colon cancer	0.0391	0.139	CbGbCtD
Tolterodine—CHRM5—epithelium—colon cancer	0.0165	0.0555	CbGeAlD
Tolterodine—Dementia—Methotrexate—colon cancer	0.0128	0.0305	CcSEcCtD
Tolterodine—Memory impairment—Capecitabine—colon cancer	0.00899	0.0214	CcSEcCtD
Tolterodine—CHRM3—smooth muscle tissue—colon cancer	0.00887	0.0299	CbGeAlD
Tolterodine—CHRM3—renal system—colon cancer	0.00854	0.0288	CbGeAlD
Tolterodine—Disorientation—Fluorouracil—colon cancer	0.00819	0.0195	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Irinotecan—colon cancer	0.00791	0.0188	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Capecitabine—colon cancer	0.00781	0.0186	CcSEcCtD
Tolterodine—KCNH2—renal system—colon cancer	0.00757	0.0255	CbGeAlD
Tolterodine—Urinary retention—Vincristine—colon cancer	0.00747	0.0178	CcSEcCtD
Tolterodine—CHRM3—digestive system—colon cancer	0.007	0.0236	CbGeAlD
Tolterodine—Influenza like illness—Capecitabine—colon cancer	0.00685	0.0163	CcSEcCtD
Tolterodine—Dry skin—Fluorouracil—colon cancer	0.00672	0.016	CcSEcCtD
Tolterodine—Dry eye—Capecitabine—colon cancer	0.00652	0.0155	CcSEcCtD
Tolterodine—CYP2C19—digestive system—colon cancer	0.00651	0.022	CbGeAlD
Tolterodine—Dysuria—Vincristine—colon cancer	0.00635	0.0151	CcSEcCtD
Tolterodine—Abnormal vision—Capecitabine—colon cancer	0.00615	0.0146	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Irinotecan—colon cancer	0.00615	0.0146	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00589	0.014	CcSEcCtD
Tolterodine—CYP2C19—vagina—colon cancer	0.00575	0.0194	CbGeAlD
Tolterodine—KCNH2—bone marrow—colon cancer	0.00572	0.0193	CbGeAlD
Tolterodine—Urinary tract infection—Fluorouracil—colon cancer	0.00549	0.0131	CcSEcCtD
Tolterodine—KCNH2—vagina—colon cancer	0.00548	0.0185	CbGeAlD
Tolterodine—Hallucination—Vincristine—colon cancer	0.00541	0.0129	CcSEcCtD
Tolterodine—Sinusitis—Fluorouracil—colon cancer	0.0053	0.0126	CcSEcCtD
Tolterodine—Visual impairment—Irinotecan—colon cancer	0.0051	0.0121	CcSEcCtD
Tolterodine—CYP2C9—digestive system—colon cancer	0.00505	0.017	CbGeAlD
Tolterodine—Flushing—Irinotecan—colon cancer	0.00491	0.0117	CcSEcCtD
Tolterodine—Urinary retention—Capecitabine—colon cancer	0.00487	0.0116	CcSEcCtD
Tolterodine—CYP2C19—liver—colon cancer	0.00485	0.0164	CbGeAlD
Tolterodine—Dry skin—Capecitabine—colon cancer	0.00469	0.0112	CcSEcCtD
Tolterodine—CYP3A4—renal system—colon cancer	0.00469	0.0158	CbGeAlD
Tolterodine—CYP2D6—renal system—colon cancer	0.00462	0.0156	CbGeAlD
Tolterodine—Flatulence—Irinotecan—colon cancer	0.00454	0.0108	CcSEcCtD
Tolterodine—Bronchitis—Capecitabine—colon cancer	0.00426	0.0101	CcSEcCtD
Tolterodine—Vertigo—Vincristine—colon cancer	0.00425	0.0101	CcSEcCtD
Tolterodine—Vertigo—Irinotecan—colon cancer	0.00414	0.00985	CcSEcCtD
Tolterodine—Dysuria—Capecitabine—colon cancer	0.00414	0.00985	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Capecitabine—colon cancer	0.00411	0.00979	CcSEcCtD
Tolterodine—Weight increased—Capecitabine—colon cancer	0.00403	0.00959	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—colon cancer	0.00394	0.00937	CcSEcCtD
Tolterodine—Anaphylactic shock—Vincristine—colon cancer	0.00386	0.00919	CcSEcCtD
Tolterodine—Oedema—Vincristine—colon cancer	0.00386	0.00919	CcSEcCtD
Tolterodine—CYP3A4—digestive system—colon cancer	0.00385	0.013	CbGeAlD
Tolterodine—Infection—Vincristine—colon cancer	0.00384	0.00913	CcSEcCtD
Tolterodine—Urinary tract infection—Capecitabine—colon cancer	0.00384	0.00913	CcSEcCtD
Tolterodine—Confusional state—Irinotecan—colon cancer	0.00379	0.00902	CcSEcCtD
Tolterodine—CYP2D6—digestive system—colon cancer	0.00379	0.0128	CbGeAlD
Tolterodine—Anaphylactic shock—Irinotecan—colon cancer	0.00376	0.00895	CcSEcCtD
Tolterodine—Oedema—Irinotecan—colon cancer	0.00376	0.00895	CcSEcCtD
Tolterodine—CYP2C9—liver—colon cancer	0.00376	0.0127	CbGeAlD
Tolterodine—Chest pain—Fluorouracil—colon cancer	0.00376	0.00894	CcSEcCtD
Tolterodine—Infection—Irinotecan—colon cancer	0.00374	0.00889	CcSEcCtD
Tolterodine—Confusional state—Fluorouracil—colon cancer	0.00363	0.00864	CcSEcCtD
Tolterodine—Oedema—Fluorouracil—colon cancer	0.0036	0.00857	CcSEcCtD
Tolterodine—Anaphylactic shock—Fluorouracil—colon cancer	0.0036	0.00857	CcSEcCtD
Tolterodine—Infection—Fluorouracil—colon cancer	0.00358	0.00852	CcSEcCtD
Tolterodine—KCNH2—lymph node—colon cancer	0.00355	0.012	CbGeAlD
Tolterodine—Musculoskeletal discomfort—Vincristine—colon cancer	0.00352	0.00837	CcSEcCtD
Tolterodine—Tachycardia—Fluorouracil—colon cancer	0.00352	0.00837	CcSEcCtD
Tolterodine—Oedema peripheral—Capecitabine—colon cancer	0.00349	0.00831	CcSEcCtD
Tolterodine—Visual impairment—Capecitabine—colon cancer	0.00341	0.00812	CcSEcCtD
Tolterodine—Somnolence—Irinotecan—colon cancer	0.00334	0.00796	CcSEcCtD
Tolterodine—Fatigue—Vincristine—colon cancer	0.00333	0.00792	CcSEcCtD
Tolterodine—Dyspepsia—Irinotecan—colon cancer	0.00331	0.00788	CcSEcCtD
Tolterodine—Constipation—Vincristine—colon cancer	0.0033	0.00786	CcSEcCtD
Tolterodine—Pain—Vincristine—colon cancer	0.0033	0.00786	CcSEcCtD
Tolterodine—Flushing—Capecitabine—colon cancer	0.00329	0.00782	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00328	0.00781	CcSEcCtD
Tolterodine—Fatigue—Irinotecan—colon cancer	0.00324	0.00772	CcSEcCtD
Tolterodine—Pain—Irinotecan—colon cancer	0.00322	0.00765	CcSEcCtD
Tolterodine—Constipation—Irinotecan—colon cancer	0.00322	0.00765	CcSEcCtD
Tolterodine—Somnolence—Fluorouracil—colon cancer	0.0032	0.00762	CcSEcCtD
Tolterodine—Dyspepsia—Fluorouracil—colon cancer	0.00317	0.00755	CcSEcCtD
Tolterodine—Gastrointestinal pain—Vincristine—colon cancer	0.00316	0.00751	CcSEcCtD
Tolterodine—Feeling abnormal—Irinotecan—colon cancer	0.0031	0.00737	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—colon cancer	0.00308	0.00733	CcSEcCtD
Tolterodine—Pain—Fluorouracil—colon cancer	0.00308	0.00733	CcSEcCtD
Tolterodine—Gastrointestinal pain—Irinotecan—colon cancer	0.00308	0.00732	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—colon cancer	0.00306	0.00729	CcSEcCtD
Tolterodine—Abdominal pain—Vincristine—colon cancer	0.00305	0.00726	CcSEcCtD
Tolterodine—Flatulence—Capecitabine—colon cancer	0.00304	0.00723	CcSEcCtD
Tolterodine—Abdominal pain—Irinotecan—colon cancer	0.00297	0.00707	CcSEcCtD
Tolterodine—Feeling abnormal—Fluorouracil—colon cancer	0.00297	0.00706	CcSEcCtD
Tolterodine—CYP3A4—liver—colon cancer	0.00287	0.00967	CbGeAlD
Tolterodine—Hypersensitivity—Vincristine—colon cancer	0.00285	0.00677	CcSEcCtD
Tolterodine—CYP2D6—liver—colon cancer	0.00282	0.00952	CbGeAlD
Tolterodine—Vertigo—Capecitabine—colon cancer	0.00277	0.00659	CcSEcCtD
Tolterodine—Hypersensitivity—Irinotecan—colon cancer	0.00277	0.00659	CcSEcCtD
Tolterodine—Asthenia—Vincristine—colon cancer	0.00277	0.00659	CcSEcCtD
Tolterodine—Palpitations—Capecitabine—colon cancer	0.00273	0.00649	CcSEcCtD
Tolterodine—Asthenia—Irinotecan—colon cancer	0.0027	0.00642	CcSEcCtD
Tolterodine—Hypersensitivity—Fluorouracil—colon cancer	0.00265	0.00632	CcSEcCtD
Tolterodine—Diarrhoea—Vincristine—colon cancer	0.00264	0.00629	CcSEcCtD
Tolterodine—Arthralgia—Capecitabine—colon cancer	0.00263	0.00625	CcSEcCtD
Tolterodine—Chest pain—Capecitabine—colon cancer	0.00263	0.00625	CcSEcCtD
Tolterodine—Anxiety—Capecitabine—colon cancer	0.00262	0.00623	CcSEcCtD
Tolterodine—Diarrhoea—Irinotecan—colon cancer	0.00257	0.00612	CcSEcCtD
Tolterodine—Dry mouth—Capecitabine—colon cancer	0.00257	0.00611	CcSEcCtD
Tolterodine—Dizziness—Vincristine—colon cancer	0.00255	0.00608	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—colon cancer	0.00254	0.00605	CcSEcCtD
Tolterodine—Confusional state—Capecitabine—colon cancer	0.00254	0.00604	CcSEcCtD
Tolterodine—Oedema—Capecitabine—colon cancer	0.00252	0.00599	CcSEcCtD
Tolterodine—Infection—Capecitabine—colon cancer	0.0025	0.00595	CcSEcCtD
Tolterodine—Dizziness—Irinotecan—colon cancer	0.00249	0.00592	CcSEcCtD
Tolterodine—Diarrhoea—Fluorouracil—colon cancer	0.00246	0.00586	CcSEcCtD
Tolterodine—Tachycardia—Capecitabine—colon cancer	0.00246	0.00585	CcSEcCtD
Tolterodine—Headache—Vincristine—colon cancer	0.00242	0.00576	CcSEcCtD
Tolterodine—Dizziness—Fluorouracil—colon cancer	0.00238	0.00567	CcSEcCtD
Tolterodine—Headache—Irinotecan—colon cancer	0.00236	0.00561	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00229	0.00546	CcSEcCtD
Tolterodine—Headache—Fluorouracil—colon cancer	0.00226	0.00537	CcSEcCtD
Tolterodine—Dyspepsia—Capecitabine—colon cancer	0.00222	0.00527	CcSEcCtD
Tolterodine—Fatigue—Capecitabine—colon cancer	0.00217	0.00516	CcSEcCtD
Tolterodine—Pain—Capecitabine—colon cancer	0.00215	0.00512	CcSEcCtD
Tolterodine—Constipation—Capecitabine—colon cancer	0.00215	0.00512	CcSEcCtD
Tolterodine—Feeling abnormal—Capecitabine—colon cancer	0.00207	0.00494	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—colon cancer	0.00206	0.00491	CcSEcCtD
Tolterodine—Gastrointestinal pain—Capecitabine—colon cancer	0.00206	0.0049	CcSEcCtD
Tolterodine—Abdominal pain—Capecitabine—colon cancer	0.00199	0.00473	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—colon cancer	0.00195	0.00465	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—colon cancer	0.00195	0.00465	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—colon cancer	0.00189	0.0045	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—colon cancer	0.00187	0.00446	CcSEcCtD
Tolterodine—Infection—Methotrexate—colon cancer	0.00186	0.00443	CcSEcCtD
Tolterodine—Hypersensitivity—Capecitabine—colon cancer	0.00185	0.00441	CcSEcCtD
Tolterodine—Asthenia—Capecitabine—colon cancer	0.00181	0.0043	CcSEcCtD
Tolterodine—Diarrhoea—Capecitabine—colon cancer	0.00172	0.0041	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00171	0.00406	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—colon cancer	0.00167	0.00396	CcSEcCtD
Tolterodine—Dizziness—Capecitabine—colon cancer	0.00166	0.00396	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—colon cancer	0.00165	0.00392	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—colon cancer	0.00162	0.00384	CcSEcCtD
Tolterodine—Pain—Methotrexate—colon cancer	0.0016	0.00381	CcSEcCtD
Tolterodine—Headache—Capecitabine—colon cancer	0.00158	0.00375	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—colon cancer	0.00154	0.00367	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—colon cancer	0.00153	0.00365	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—colon cancer	0.00148	0.00352	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—colon cancer	0.00138	0.00329	CcSEcCtD
Tolterodine—Asthenia—Methotrexate—colon cancer	0.00134	0.0032	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—colon cancer	0.00128	0.00305	CcSEcCtD
Tolterodine—Fesoterodine—ABCB1—colon cancer	0.00126	1	CrCbGaD
Tolterodine—Dizziness—Methotrexate—colon cancer	0.00124	0.00295	CcSEcCtD
Tolterodine—Headache—Methotrexate—colon cancer	0.00117	0.00279	CcSEcCtD
